Jazz Pharmaceuticals (JAZZ) Current Assets (2010 - 2026)
Jazz Pharmaceuticals' quarterly Current Assets came in at $4.6 billion in Q1 2026, up 11.03% year-on-year from $4.1 billion in Q1 2025, and up 10.01% quarter-over-quarter from $4.2 billion in Q4 2025.
Jazz Pharmaceuticals has reported Current Assets for 17 years, with the latest figure at $4.6 billion in Q1 2026.
- For the quarter ending Q1 2026, Current Assets rose 11.03% year-over-year to $4.6 billion; the trailing twelve-month figure through Mar 2026 stood at $4.6 billion (up 11.03% YoY), and the FY2025 full-year result was $4.2 billion, down 10.0% from the prior year.
- Current Assets for Q1 2026 stood at $4.6 billion, up from $4.2 billion in the prior quarter.
- The five-year high for Current Assets was $4.6 billion in Q4 2024, with the low at $2.5 billion in Q1 2022.
- Average Current Assets over 5 years is $3.5 billion, with a median of $3.4 billion recorded in 2023.
- Year-over-year, Current Assets decreased 21.03% in 2022 and jumped 35.27% in 2024.
- Tracing JAZZ's Current Assets over 5 years: stood at $2.6 billion in 2022, then jumped by 31.82% to $3.4 billion in 2023, then jumped by 34.74% to $4.6 billion in 2024, then dropped by 10.0% to $4.2 billion in 2025, then rose by 10.01% to $4.6 billion in 2026.
- The last three Current Assets figures came in at $4.6 billion (Q1 2026), $4.2 billion (Q4 2025), and $3.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 10.37 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 37.31 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.25 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 73.04 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 3.59 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 11.73 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.21 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.22 Bn |
| 10 | Jazz Pharmaceuticals | 14.64 Bn | 12.79 Bn | 934.80 Mn | 4.58 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.58 Bn |
| Dec 31, 2025 | 4.17 Bn |
| Sep 30, 2025 | 3.76 Bn |
| Jun 30, 2025 | 3.35 Bn |
| Mar 31, 2025 | 4.13 Bn |
| Dec 31, 2024 | 4.63 Bn |
| Sep 30, 2024 | 4.39 Bn |
| Jun 30, 2024 | 3.68 Bn |
| Mar 31, 2024 | 3.54 Bn |
| Dec 31, 2023 | 3.44 Bn |
| Sep 30, 2023 | 3.25 Bn |
| Jun 30, 2023 | 3.01 Bn |
| Mar 31, 2023 | 2.78 Bn |
| Dec 31, 2022 | 2.61 Bn |
| Sep 30, 2022 | 2.57 Bn |
| Jun 30, 2022 | 2.59 Bn |
| Mar 31, 2022 | 2.50 Bn |
| Dec 31, 2021 | 2.61 Bn |
| Sep 30, 2021 | 2.63 Bn |
| Jun 30, 2021 | 2.95 Bn |
| Mar 31, 2021 | 3.17 Bn |
| Dec 31, 2020 | 2.84 Bn |
| Sep 30, 2020 | 2.56 Bn |
| Jun 30, 2020 | 2.30 Bn |
| Mar 31, 2020 | 1.52 Bn |
| Dec 31, 2019 | 1.63 Bn |
| Sep 30, 2019 | 1.52 Bn |
| Jun 30, 2019 | 1.37 Bn |
| Mar 31, 2019 | 1.31 Bn |
| Dec 31, 2018 | 1.23 Bn |
| Sep 30, 2018 | 1.46 Bn |
| Jun 30, 2018 | 1.31 Bn |
| Mar 31, 2018 | 1.13 Bn |
| Dec 31, 2017 | 968.28 Mn |
| Sep 30, 2017 | 830.94 Mn |
| Jun 30, 2017 | 662.50 Mn |
| Mar 31, 2017 | 752.85 Mn |
| Dec 31, 2016 | 748.07 Mn |
| Sep 30, 2016 | 744.23 Mn |
| Jun 30, 2016 | 1.23 Bn |
| Mar 31, 2016 | 1.27 Bn |
| Dec 31, 2015 | 1.26 Bn |
| Sep 30, 2015 | 1.31 Bn |
| Jun 30, 2015 | 1.24 Bn |
| Mar 31, 2015 | 1.10 Bn |
| Dec 31, 2014 | 1.02 Bn |
| Sep 30, 2014 | 878.52 Mn |
| Jun 30, 2014 | 544.91 Mn |
| Mar 31, 2014 | 517.32 Mn |
| Dec 31, 2013 | 864.62 Mn |
| Sep 30, 2013 | 810.07 Mn |
| Jun 30, 2013 | 734.18 Mn |
| Mar 31, 2013 | 647.37 Mn |
| Dec 31, 2012 | 551.57 Mn |
| Sep 30, 2012 | 385.01 Mn |
| Jun 30, 2012 | 300.44 Mn |
| Mar 31, 2012 | 327.14 Mn |
| Dec 31, 2011 | 199.13 Mn |
| Sep 30, 2011 | 152.14 Mn |
| Jun 30, 2011 | 136.09 Mn |
| Mar 31, 2011 | -54.44 Mn |
| Dec 31, 2010 | 74.46 Mn |